Trichoscopic Markers and Clinical Response Patterns With Ritlecitinib in Severe Alopecia Areata: 24-Week Outcomes From a Prospective Real-World Cohort

This study found that individuals with Alopecia Areata experience significantly higher social appearance anxiety compared to healthy controls, driven more by appearance-related concerns than by general anxiety or depression, highlighting the importance of targeted psychosocial assessments in their routine care.

This study describes characteristics and outcomes for adults initiating ritlecitinib for severe alopecia areata, highlighting increased hair regrowth and physician satisfaction with longer treatment durations, despite ongoing psychosocial impacts like embarrassment and anxiety among patients.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This study reviewed 39 studies with 3204 patients to identify characteristic trichoscopic findings in alopecia areata, highlighting yellow and black dots, broken, short vellus, and tapering hairs as key indicators. It found no single diagnostic trichoscopic finding but observed trichoscopy's utility in monitoring treatment response.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

This study reviewed the usefulness of trichoscopy in diagnosing and monitoring alopecia areata, noting that the technique identifies specific hair features like yellow and black dots, which are linked to the disease's chronic nature and treatment response.

This review discusses the substantial impact of alopecia areata on patients' health-related quality of life, highlighting issues such as personality changes, emotional and social difficulties, and a common occurrence of alexithymia, and emphasizes the need for more specific assessment tools.

This review presents various trichoscopic findings for diagnosing alopecia areata but reports no new clinical results, emphasizing that no single marker is pathognomonic and multiple features should be considered together.

This article updates a diagnostic tool (SALT II) for assessing hair loss by adding more precise measurements of scalp surface area, particularly useful for various types of alopecia.

This study found that patients with alopecia areata experience significant impairments in health-related quality of life, notably affecting mental health, according to various quality of life assessment tools.

This review discusses alopecia areata, highlighting its autoimmune aspects, environmental triggers, and current treatment options, but reports no new clinical results; recent studies suggest JAK pathway intervention may offer therapeutic potential.

This study found that certain trichoscopic patterns, like exclamation mark hairs, were associated with active or mild alopecia areata in Turkish patients, aiding in diagnosis and prediction of the disease.

This review discusses the application of trichoscopy in diagnosing various hair and scalp diseases and reports no new clinical results; the authors emphasize its role as a non-invasive diagnostic tool.